Johnson & Johnson Adds Eprex Anemia Drug to Recall List

Posted on

Johnson & Johnson is conducting yet another recall, this time of its Eprex anemia drug, due to a lack of potency, according to recent news sources.

The recall affects about 200,000 syringes of the Eprex anemia drug. The drug is sold at the wholesale and pharmacy level. Johnson & Johnson believes most of the product has already been consumed, leaving about 6,300 syringes on the market. Seventeen different countries are affected by the recall, including the U.K. and Canada. The United States is not among the countries affected.

No illnesses or injuries have currently been reported in regards to the drug, according to Johnson & Johnson.

This year, Johnson & Johnson seems to be announcing one recall after another, with an expected loss of sales totaling about $900 million.

As a product defect lawyer in Los Angeles, I hope that no one’s health is adversely affected by consuming this drug. In my experience as a product liability lawyer, I know that altered drugs or drugs that have been tampered with can lead to serious long-term suffering. If you have been injured by a drug, I advise you to contact a personal injury lawyer to protect your rights and discuss your legal options.